This invention is in the area of dosage formulations and methods of administering a CDK4 / 6 inhibitor for the transient protection of healthy cells, and in particular hematopoietic stem and
progenitor cells (HSPC), from damage associated with
DNA damaging chemotherapeutic agents in subjects undergoing
DNA damaging chemotherapeutic therapies for the treatment of proliferative disorders. In one aspect, improved protection of healthy cells is disclosed using a dosage that provides desirable pharmacokinetic and pharmacodynamic characteristics, including AUC, Tmax, Cmax, dosage-corrected AUC, and dosage-corrected Cmax. In another aspect, a method of treating a subject undergoing
chemotherapy for the treatment of a CDK 4 / 6-replication independent cellular proliferation disorder by administering Compound 1 is provided.